224 related articles for article (PubMed ID: 18768809)
1. Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice.
Fujishita T; Aoki K; Lane HA; Aoki M; Taketo MM
Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13544-9. PubMed ID: 18768809
[TBL] [Abstract][Full Text] [Related]
2. The role of mTORC1 pathway in intestinal tumorigenesis.
Fujishita T; Aoki M; Taketo MM
Cell Cycle; 2009 Nov; 8(22):3684-7. PubMed ID: 19855161
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic mutations in adenomatous polyposis coli (Apc) activate mechanistic target of rapamycin complex 1 (mTORC1) in mice and zebrafish.
Valvezan AJ; Huang J; Lengner CJ; Pack M; Klein PS
Dis Model Mech; 2014 Jan; 7(1):63-71. PubMed ID: 24092877
[TBL] [Abstract][Full Text] [Related]
4. Colonic polyposis caused by mTOR-mediated chromosomal instability in Apc+/Delta716 Cdx2+/- compound mutant mice.
Aoki K; Tamai Y; Horiike S; Oshima M; Taketo MM
Nat Genet; 2003 Dec; 35(4):323-30. PubMed ID: 14625550
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of intestinal adenoma formation in APC(Min/+) mice by Riccardin D, a natural product derived from liverwort plant Dumortiera hirsuta.
Liu HP; Gao ZH; Cui SX; Sun DF; Wang Y; Zhao CR; Lou HX; Qu XJ
PLoS One; 2012; 7(3):e33243. PubMed ID: 22432006
[TBL] [Abstract][Full Text] [Related]
6. Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis.
Pollizzi K; Malinowska-Kolodziej I; Stumm M; Lane H; Kwiatkowski D
Mol Cancer; 2009 Jun; 8():38. PubMed ID: 19527517
[TBL] [Abstract][Full Text] [Related]
7. JNK signaling promotes intestinal tumorigenesis through activation of mTOR complex 1 in Apc(Δ716) mice.
Fujishita T; Aoki M; Taketo MM
Gastroenterology; 2011 May; 140(5):1556-63.e6. PubMed ID: 21320501
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of mTORC1 by RAD001 (everolimus) potentiates the effects of 1,25-dihydroxyvitamin D(3) to induce growth arrest and differentiation of AML cells in vitro and in vivo.
Yang J; Ikezoe T; Nishioka C; Ni L; Koeffler HP; Yokoyama A
Exp Hematol; 2010 Aug; 38(8):666-76. PubMed ID: 20382200
[TBL] [Abstract][Full Text] [Related]
9. Reduced level of smoothened suppresses intestinal tumorigenesis by down-regulation of Wnt signaling.
Arimura S; Matsunaga A; Kitamura T; Aoki K; Aoki M; Taketo MM
Gastroenterology; 2009 Aug; 137(2):629-38. PubMed ID: 19427313
[TBL] [Abstract][Full Text] [Related]
10. mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice.
Thiem S; Pierce TP; Palmieri M; Putoczki TL; Buchert M; Preaudet A; Farid RO; Love C; Catimel B; Lei Z; Rozen S; Gopalakrishnan V; Schaper F; Hallek M; Boussioutas A; Tan P; Jarnicki A; Ernst M
J Clin Invest; 2013 Feb; 123(2):767-81. PubMed ID: 23321674
[TBL] [Abstract][Full Text] [Related]
11. Rapamycin inhibition of polyposis and progression to dysplasia in a mouse model.
Hardiman KM; Liu J; Feng Y; Greenson JK; Fearon ER
PLoS One; 2014; 9(4):e96023. PubMed ID: 24763434
[TBL] [Abstract][Full Text] [Related]
12. mTORC1-mediated translational elongation limits intestinal tumour initiation and growth.
Faller WJ; Jackson TJ; Knight JR; Ridgway RA; Jamieson T; Karim SA; Jones C; Radulescu S; Huels DJ; Myant KB; Dudek KM; Casey HA; Scopelliti A; Cordero JB; Vidal M; Pende M; Ryazanov AG; Sonenberg N; Meyuhas O; Hall MN; Bushell M; Willis AE; Sansom OJ
Nature; 2015 Jan; 517(7535):497-500. PubMed ID: 25383520
[TBL] [Abstract][Full Text] [Related]
13. The threshold level of adenomatous polyposis coli protein for mouse intestinal tumorigenesis.
Li Q; Ishikawa TO; Oshima M; Taketo MM
Cancer Res; 2005 Oct; 65(19):8622-7. PubMed ID: 16204028
[TBL] [Abstract][Full Text] [Related]
14. Dvl2 promotes intestinal length and neoplasia in the ApcMin mouse model for colorectal cancer.
Metcalfe C; Ibrahim AE; Graeb M; de la Roche M; Schwarz-Romond T; Fiedler M; Winton DJ; Corfield A; Bienz M
Cancer Res; 2010 Aug; 70(16):6629-38. PubMed ID: 20663899
[TBL] [Abstract][Full Text] [Related]
15. A knock-in mouse model reveals roles for nuclear Apc in cell proliferation, Wnt signal inhibition and tumor suppression.
Zeineldin M; Cunningham J; McGuinness W; Alltizer P; Cowley B; Blanchat B; Xu W; Pinson D; Neufeld KL
Oncogene; 2012 May; 31(19):2423-37. PubMed ID: 21996741
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer.
Guigon CJ; Fozzatti L; Lu C; Willingham MC; Cheng SY
Carcinogenesis; 2010 Jul; 31(7):1284-91. PubMed ID: 20299527
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps.
Seno H; Oshima M; Ishikawa TO; Oshima H; Takaku K; Chiba T; Narumiya S; Taketo MM
Cancer Res; 2002 Jan; 62(2):506-11. PubMed ID: 11809702
[TBL] [Abstract][Full Text] [Related]
18. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
Feldman ME; Apsel B; Uotila A; Loewith R; Knight ZA; Ruggero D; Shokat KM
PLoS Biol; 2009 Feb; 7(2):e38. PubMed ID: 19209957
[TBL] [Abstract][Full Text] [Related]
19. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
20. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.
Tamburini J; Chapuis N; Bardet V; Park S; Sujobert P; Willems L; Ifrah N; Dreyfus F; Mayeux P; Lacombe C; Bouscary D
Blood; 2008 Jan; 111(1):379-82. PubMed ID: 17878402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
